rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
7
|
pubmed:dateCreated |
2004-7-1
|
pubmed:abstractText |
Behçet's disease (BD) with uveoretinitis is a chronic refractory disease accompanied by ocular attacks. As the decrease in visual acuity due to ocular attack is seriously life-threatening, development of a new drug is anticipated. Since tumor necrosis factor-a (TNF-a) is involved in the symptoms of BD, particularly the activity of ocular symptoms, suppression of TNF-a might be effective in treating BD with uveoretinitis. We conducted a clinical trial of infliximab, an anti-TNF-a chimeric monoclonal antibody, in patients with BD.
|
pubmed:commentsCorrections |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0315-162X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1362-8
|
pubmed:dateRevised |
2005-9-19
|
pubmed:meshHeading |
pubmed-meshheading:15229958-Adolescent,
pubmed-meshheading:15229958-Adult,
pubmed-meshheading:15229958-Antibodies, Monoclonal,
pubmed-meshheading:15229958-Antirheumatic Agents,
pubmed-meshheading:15229958-Behcet Syndrome,
pubmed-meshheading:15229958-Dose-Response Relationship, Drug,
pubmed-meshheading:15229958-Female,
pubmed-meshheading:15229958-Humans,
pubmed-meshheading:15229958-Male,
pubmed-meshheading:15229958-Middle Aged,
pubmed-meshheading:15229958-Retinitis,
pubmed-meshheading:15229958-Treatment Outcome,
pubmed-meshheading:15229958-Tumor Necrosis Factor-alpha,
pubmed-meshheading:15229958-Uveitis
|
pubmed:year |
2004
|
pubmed:articleTitle |
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
|
pubmed:affiliation |
Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-Ku, Sapporo 060-8638, Japan.
|
pubmed:publicationType |
Journal Article
|